Adalimumab is the first fully humanized monoclonal anti-tumor necrosis factor alpha (TNF-α) antibody. This drug has been shown to be of benefit in patients with inflammatory diseases in which TNF-α is involved, such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn`s disease. As the use of adalimumab is becoming more widespread, cutaneous side effects are being increasingly reported. Various dermatologic adverse events have been reported in the literature, including injection site reactions, psoriasis-like eruption and pityriasis rosea. Herein, we describe a case of GA associated with adalimumab treatment for adult-onset Still`s disease, which has not been reported in Korea.